Cevira is one of Photocure’s promising pipeline products and is being developed as a new and innovative breakthrough for the treatment of precancerous lesions of the cervix. The newly granted patent protects the Cevira device including its use in combination with the Cevira drug until 2029.
This key patent in Photocure’s Cevira portfolio complements the company’s proprietary European patent, which claims different aspects of the Cevira device and Photocure’s registered European Community design, which covers the appearance of the device, i.e. lines, contours, colours, shape, texture and/or materials. The patent expires in 2029, while the design expires in April 2038. In US, Photocure has patents granted to 2030.
The approval of this latest patent is a key milestone for us in our continued work to secure the long-term value of Cevira. The new patent further strengthens Photocure’s robust patent portfolio and provides Cevira market exclusivity for the long-term. Cevira is a key asset for us, with the potential to not only treat HPV induced cervical high grade disease but also to prevent the development of cervical cancer, which affects more than 500,000 women annually.” said Kjetil Hestdal, President and CEO of Photocure.
For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: firstname.lastname@example.org
CFO Erik Dahl
Tel: +47 450 55 000, Email: email@example.com